Clinical Trial Deaths Lead Ariad To Halt Iclusig Sales

Law360, New York (October 31, 2013, 6:51 PM EDT) -- Ariad Pharmaceuticals Inc. on Thursday suspended sales of leukemia drug Iclusig at the request of the U.S. Food and Drug Administration after more than a dozen participants in clinical trials died and many others became seriously ill as a result of blood clots.

The dramatic development came three weeks after FDA began investigating vascular side effects and was apparently spurred by eye-popping rates of adverse events among participants in trials being conducted after the chemotherapy drug won accelerated approval in December to treat two rare blood...
To view the full article, register now.